(Q35606384)

English

HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era.

scientific article published on 14 November 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era. (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Burkitt lymphoma

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

J A Rodrigo

1

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

L K Hicks

2

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

M C Cheung

3

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

K W Song

4

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

H Ezzat

5

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

C S Leger

6

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

J Boro

7

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

J S G Montaner

8

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

M Harris

9

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

H A Leitch

10

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

publication date

14 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

Advances in Hematology

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

2012

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

735392

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

copyright license

Creative Commons Attribution 3.0 Unported

1 January 2012

1 reference

April 2022 Public Data File from Crossref

Creative Commons Attribution 3.0 Unported

0 references

copyright status

1 reference

April 2022 Public Data File from Crossref

AIDS-related Burkitt lymphoma in the United States: what do age and CD4 lymphocyte patterns tell us about etiology and/or biology?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235428

12 July 2018

Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235428

12 July 2018

Burkitt lymphoma in adults

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235428

12 July 2018

Improving outcomes for patients with Burkitt lymphoma and HIV.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235428

12 July 2018

Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235428

12 July 2018

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235428

12 July 2018

Delayed-onset grade 4 neutropenia associated with rituximab therapy in a patient with lymphoma: case report and literature review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235428

12 July 2018

Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235428

12 July 2018

Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235428

12 July 2018

Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235428

12 July 2018

Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235428

12 July 2018

Molecular biology of Burkitt's lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235428

12 July 2018

Changes in acquired immunodeficiency syndrome-related lymphoma since the introduction of highly active antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235428

12 July 2018

Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235428

12 July 2018

Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235428

12 July 2018

Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235428

12 July 2018

Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma--outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantat

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235428

12 July 2018

Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235428

12 July 2018

Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235428

12 July 2018

Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F735392

21 January 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F735392

21 January 2018

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F735392

21 January 2018

Improved survival in HIV-associated diffuse large B-cell lymphoma with the addition of rituximab to chemotherapy in patients receiving highly active antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F735392

21 January 2018

Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials.

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F735392

21 January 2018

AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F735392

21 January 2018

Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F735392

21 January 2018

Methylene Blue for the Treatment and Prophylaxis of Ifosfamide-induced Encephalopathy

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F735392

21 January 2018

Autologous stem cell transplantation for HIV-associated lymphoma

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F735392

21 January 2018

High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients.

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F735392

21 January 2018

Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F735392

21 January 2018

Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F735392

21 January 2018

The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235428

25 September 2018

Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3235428

25 September 2018

Rituximab therapy for HIV-associated Castleman disease

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F735392

21 January 2018

Improved outcome of AIDS-related lymphoma in patients with virologic response to highly active antiretroviral therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22190945

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Eighty-one percent event-free survival in advanced Burkitt's lymphoma/leukemia: no differences in outcome between pediatric and adult patients treated with the same intensive pediatric protocol

1 reference

https://pubmed.ncbi.nlm.nih.gov/22190945

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Delayed-onset neutropenia associated with rituximab therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22190945

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Small noncleaved, non-Burkitt's (Burkit-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation

1 reference

https://pubmed.ncbi.nlm.nih.gov/22190945

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine

1 reference

https://pubmed.ncbi.nlm.nih.gov/22190945

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Changing incidence and survival in patients with aids-related non-Hodgkin's lymphomas in the era of highly active antiretroviral therapy (HAART)

1 reference

https://pubmed.ncbi.nlm.nih.gov/22190945

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%

1 reference

https://pubmed.ncbi.nlm.nih.gov/22190945

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1155/2012/735392

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35606384&oldid=1801510282"